The Michael J Fox Foundation

#Alzheimer's #Alzheimer's Drug Discovery Foundation #Biomarkers #Drug discovery #Parkinson's #Partnership #The Michael J Fox Foundation #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

US$5m partnership targets Alzheimer’s and Parkinson’s biomarkers

The Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) and The Michael J. Fox Foundation (MJFF) have announced a new US$5 million partnership to accelerate the development of minimally invasive biomarkers for measuring pathologies associated with Parkinson’s and Alzheimer’s diseases. Isobel Coleman, Chief Executive Officer of the Alzheimer’s Drug Discovery… Read More

#News

Neurons in Parkinson's disease
#Nautilus Biotechnology #Neurodegenerative disorders #Parkinson's #The Michael J Fox Foundation

$1.6m collaboration to advance Parkinson’s proteomics research 

A $1.6 million research effort is set to advance single-molecule proteomics research in Parkinson’s disease (PD).  Life sciences company Nautilus Biotechnology has partnered with Weill Cornell Medicine-Qatar (WCM-Q) and The Michael J Fox Foundation (MJFF) to study the connection between the alpha-synuclein (aSyn) protein and PD.   The project will combine WCM-Q’s lab expertise in… Read More

#Business & Investment #News

Parkinson's disease
#Charity #Funding #IRLAB Therapeutics #Parkinson's #The Michael J Fox Foundation

Parkinson’s charity awards $2m to support apathy treatment

Swedish company IRLAB Therapeutics has been awarded funding of over $2 million from The Michael J Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to conduct a Phase I clinical study of IRL757, a drug candidate in development as a novel treatment of… Read More

#News